Cancer bio 11/17: Tumor angiogenesis and metabolism

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/54

encourage image

There's no tags or description

Looks like no tags are added yet.

55 Terms

1
New cards

8 hallmarks of cancer

self-sufficiency in growth signaling

insensitivity to growth inhibition

limitless replication potential

evasion of apoptosis

neo-angiogenesis

tissue invasion and metastasis

metabolic reprogramming

evasion of immune system

2
New cards

how far away from a blood vessel can cancer cells survive

human melanoma: 85um

rat prostate cancer: 110um

3
New cards

EF5 staining

clinical test to test for oxygen

if EF5 is oxygenated, will convert to EF5-S-Cys-ptotein covalent adducts which can be visualized in staining. if no staining that means no oxygen present

visualize hypoxic areas → farther away from blood vessels have less staining

4
New cards

how did they determine if tumor growth requires angiogenesis

followed tumor growth in two regions of eye

both had all nutrients necessary provided

large growth in iris, which is able to support angiogenesis

no growth in anterior chamber, which is NOT able to support angiogenesis

5
New cards

what happens when breast cancer cells are injected into angiogensis-deficient mice

no tumors

6
New cards

angiogenesis-deficient mice KO genes

het ld1

full KO ld3

7
New cards

tumor blood vessel growth happens via

upregulation of vascular endothelial growth factor (VEGF)

8
New cards

VEGF

vascular endothelial growth factor

upregulation allows for tumor blood vessel growth

9
New cards

angiogenesis positive feedback loop

tumors cause increased angiogenesis

new blood supply causes increased tumor growth

10
New cards

what cells contribute to angiogenesis

nude mouse transplanted with human HSCs, mouse tumor cells implanted, human endothelial markers found in new vasculature

  • human endothelial markers PECAM, CD34, VEGFR2 in blood vessels

  • angiogenesis recruits from endothelial cells in bone marrow, not tumor cells


11
New cards

mechanisms of blood vessel formation

sprouting angiogenesis

vasulogenesis

vascular mimicry

tumor cell → EC differentiation

12
New cards

sprouting angiogenesis

tip cell extrudes and connects to another tube, forming circle so nutrients can travel

13
New cards

vasulogenesis

endothelial precursor cells differentiate into endothelial cells

14
New cards

vascular mimicry

tumor cells line new blood vessels

15
New cards

tumor cell → EC differentiation

cancer stem-like cells differentiate into ECs

only way to differentiate is with genetic analysis

16
New cards

normal tissue vasculature

linear vessels

smooth layers of endothelium

supported by pericytes

17
New cards

tumor tissue vasculature

irregularly shaped vessels

many dead-ends

two few pericytes (less stable)

leaky

more thick and rigid matrix

18
New cards

what happens to pH of cells as O2 levels decrease (moving away from blood vessel)

decreasing pH, cells make more lactic acid

19
New cards

HIF1/2

upregulated in hypotoxic environments → induces transcription of genes for glycolysis, CA IX/XII (pH regulation), GLUT1,3 (glucose transporter), VEGF (angiogenesis)

20
New cards

PHD and FIH

O2 sensitive regulators of HIF-alpha via hydroxylation

PHDs hydroxylate Pro on HIF-alpha, causing VHL-mediated proteolysis → inactivation of HIF transcriptional activity

FIH hydroxylates Asn on HIF-alpha, causing blocked p300 (co-activator) recruitment → also inactivation of HIF transcriptional activity

21
New cards

HIF-alpha in high and low O2

high: active hydroxylases PHD and FIH → inactivate HIF transcriptional activity

low: inactive hydroxylases → co activators recruited → activation of transcriptional activity (50 fold upreg)

22
New cards

loss of VHL

in 90% of renal clear cell carcinoma (RCC) (most common form of kidney cancer)

van Hippel-Lindau syndrome

1:30,000

constitutively active hypoxia sugnaling

23
New cards

cancers from loss of VHL

RCC carcinoma (usually both kidneys)

hemangioblastoma (blood vessel tumors in brain, spinal cord, eye)

pheochromocytoma (adrenal gland tumor)

pancreatic neuroendocrine tumors

24
New cards

HIF2-alpha

key oncogene target of VHL in RCC

mutated VHL highly upregulates HIF2alpha → transcription factor PAX8 → more cyclin D1 and myc (uncontrolled proliferation and transformation)

25
New cards

major mechanisms regulating HIF1alpha/2alpha levels

O2 availability

control via protein synthesis

ROS mediated inhibition of PHDs

inhibition of PHDs by oncometabolites

26
New cards

O2 availability controls HIF-1/2 alpha degradation

1° mxn in hypoxia

decreased O2 → decreased OH-HIF-alpha → increased HIF-alpha

27
New cards

HIF1alpha/2alpha level control via protein synthesis

growth signaling dependent, oncogene dependent

increased signaling, increased HIF-1alpha translation

28
New cards

HIF1alpha/2alpha level control via ROS mediated inhibition of PHDs

2° mxn in hypoxia

decreased O2 → increased mitoROS —| PHDs (Cys-SH oxidation) → decreased OH-HIF-alpha → increased HIF-alpha

29
New cards

HIF1alpha/2alpha level control via inhibition of PHDs by oncometabolites

mutated Krebs cycle enzymes

oncometabolites —| PHDs → decreased OH-HIF-alpha → increased HIF-alpha

30
New cards

hypoxic tumor prognosis trend

likely poorer prognosis

tumor is able to live in unfavorable environments

hypoxic areas also are low pH which is an immunosuppressive environment

31
New cards

solutions to tumor hypoxia

spreading along existing blood vessels (glioma/glioblastoma)

invasion into surrounding tissues with normal O2 and nutrients (HIF1 dependent response)

32
New cards

rationale for anti-angiogenic therapy

majority of tumors require angiogenesis for growth

adult tissues have no need for new blood vessels

allows for avoidance of drug resistance

issue: have to take forever, turns cancer into chronic disease

33
New cards

inhibitors of angiogenesis clinical testing

avastin

endostatin

34
New cards

avastin

anti-VEGF antibody

proven efficacy for colon and renal cancer

side effects: cardiovascular

35
New cards

endostatin

natural angiogenesis inhibitor

failed in clinical trials

36
New cards

ASMase

acidic sphinogomyelinase

breaks down sphingomylein to ceramide causing apoptosis

ASMase KO mice have increased tumor volume

37
New cards

antitumor effects of radiation

direct: inhibits tumor cells → tumor shrinkage

indirect: inhibits endothelial cells → tumor shrinkage

38
New cards

anti-VEGF therapy clinical results

no tumor dormancy (initial predictions)

ineffective alone

works in combination with chemotherapy (matastatic lung, colon, renal, NOT breast (no survival benefit))

initial delay in tumor growth but not survival benefit (ovarian cancer, glioblastoma)

39
New cards

how can tumor angiogenesis be clinically beneficial

normal to extra vessel formation can allow for better drug delivery/response, immune access, less aggressive tumors

40
New cards

issues with blood vessel eradication

initial shrinkage but then regrowth of aggressive cancer, poor drug/immune access

cells on periphery that survive bc they’re closer to blood vessels and then are more aggressive

41
New cards

anti-VEGF therapy reduction of immunosuppression

VEGF-R is expressed on T killer cells. VEGF activates and causes exhaustion and loss of activity

inhibiting VEGF means it never binds

42
New cards

warburg effect

aerobic glycolysis in cancer

metabolism of glucose through lactic acid in the presence of O2

hallmark of cancer

caused by increased HIF-1

43
New cards

metabolic addiction of cancer 1: high glucose usage

warburg effect → decreased OxPhos & increased PI3K-AKT → increased glucose uptake

44
New cards

PET imaging of lymphoma with radioactive FDG

PET = positron-emission tomography

FDG = fluorodeoxyglucose → enters cells but gets trapped (not metabolized) → detected by positron emission

90% specificity and sensitivity for primary/metastatic cancers

45
New cards

PET-FDG limitations

high background in brain bc brain uses lots of glucose

46
New cards

benefit of PET-CT imaging in clinical response

CT will show abnormalities past metastatic tumors (as a scar)

PET shows when no longer active tumor

47
New cards

why do cancer cells have constitutively active glycolysis

competition for resources (GLUT1 high Vmax, GLUT3 low Km)

adaptation (rapid cycles of hypoxia and normoxia; increased carbonic anhydrases)

lactate as another energy source

immune escape (high acidity)

invasiveness (low pH kills neighbors)

48
New cards

metabolism of cancers

similar to fetal metabolism; embryonic and cancer cells need to proliferate lots

use warburg effect which produces fatty acids and nucleotides → needed for biosynthesis

49
New cards

PKM2

pyruvate kinase M2

overexpressed in tumors, fetal tissues and stem cells phosphate transfer from PEP to ADP to generate ATP

50
New cards

warburg effect molecular basis

HIF1 shuts down pyruvate to acetyl CoA transition and increased LDHA (lactate dehydrogenase) → more lactic acid and less TCA

51
New cards

mutated isocitrate dehydrogenase (IDH) in cancer

glioma, AML

majority of gliomas have mutated IDH1/2

cause alpha ketoglutarate → 2 ketoglutarate, an oncometabolite instead of succinate

IDHmut inhibitor has clinical approval

52
New cards

oncometamolites from mutations in krebs cycle enzymes

IDHmut → 2-ketoglutarate

SDHmut → highly upregulated succinate

FHmut → highly upregulated fumarate


three are all inhibitors of alphaKG dependent dioxygenases

53
New cards

metabolic addition of cancer 2: glutamine

nitrogen source and alternative energy source

nitrogen source for biosynthetic reactions

Gln → Glu → alphaKG for krebs

54
New cards

PET-Gln imaging

instead of PET-FDG (lots of background signal bc glucose, so hard to see tumor)

modify to use glutamine bc brain doesn’t use, so way less background

55
New cards

regulation of intracellular pH in hypoxic cells

CA IX needed for pH regulation → silencing decreases tumor size